OMER - Omeros Corporation logo

OMER

Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company that develops small-molecule and protein therapeutics targeting immunologic diseases, including treatments for thrombotic microangiopathy, COVID-19, and various disorders related to MASP-2.

โš•๏ธ Healthcare NASDAQ Listed 2009 $ USD
$1,000 invested 10 years ago โ†’$1,191today

Score Overview

1 Year
Scoreโ€”
Net Growth27x
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score4.9
Net Growth177.34%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-89.07%
Rev Trend20%
Revenue Consistencyโ€”
10 Years
Score
Net Growth229.10%
Net Trend60%
Net Income Consistency
Rev Growth-76.23%
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth6x
Net Trend47%
Net Income Consistency
Rev Growth6x
Rev Trend53%
Revenue Consistency

See the full market ranking โ†’

Omeros Corporation fundamental performance

Between 2020 and 2025, revenue declined from $ 73M to $ 0.00 and net income went from -$ 138M to -$ 3M. Revenue increased in 1 of those 5 years; net income in 3.

Across Omeros Corporation's full reported history, from 2009 to 2025, revenue declined from $ 1M to $ 0.00 and net income went from -$ 21M to -$ 3M. Revenue increased in 53% of the years measured; net income in 47%.

Omeros Corporation currently holds a 5-year HDB Score of 4.9 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 13.71โ€”
1 Year2025-08-12
$ 4.18227.99%
5 Years2021-08-12
$ 15.26-10.16%
10 Years2016-08-12
$ 11.5119.11%
All Time2009-10-08
$ 8.7357.04%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 9M$ 86M$ 135M
2025$ 0.00-$ 3M$ 171M
2024$ 0.00-$ 156M$ 90M
2023$ 0.00-$ 117M$ 171M
2022$ 0.00$ 47M$ 194M
2021$ 90M-$ 111M$ 157M
2020$ 73M-$ 138M$ 134M
2019$ 111M-$ 84M$ 60M
2018$ 29M-$ 126M$ 60M
2017$ 64M-$ 53M$ 83M
2016$ 41M-$ 66M$ 45M
2015$ 13M-$ 75M$ 28M
2014$ 539K-$ 73M$ 6M
2013$ 1M-$ 39M$ 14M
2012$ 6M-$ 38M$ 22M
2011$ 4M-$ 28M$ 24M
2010$ 2M-$ 29M$ 41M
IPO2009$ 1M-$ 21M$ 60M

Explore beyond OMER

You're looking at Omeros Corporation. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies